A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Hoffmann-La Roche30 enrolled

Overview

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

Conditions

HIV Infections

Interventions

SaquinavirDRUG

LamivudineDRUG

ZidovudineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV antibody positive. * CD4 count \>= 150 and \<= 500 cells/mm3. Exclusion Criteria Prior Medication: Excluded: * Prior antiretroviral therapy. * Prior protease inhibitor therapy.

Locations (3)

Davies Med Ctr / c/o HIV Institute

San Francisco, California, United States

Pacific Oaks Med Group / Rsch & Scientific Investigation

Sherman Oaks, California, United States

Columbia Presbyterian Med Ctr

New York, New York, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.